Key Takeaways
- • RNAV8 Bio selected as part of a multi-institution team to receive up to $4.4 million in ARPA-H pilot funding over one year for the PROPEL program focused on programmable RNA therapeutics.
- • PROPEL aims to establish predictable relationships between RNA sequence and therapeutic function, enabling logic-gated RNA medicines that activate only in intended locations and timeframes without genomic alteration.
- • Research team comprises RNAV8 Bio alongside the Rouskin Lab at Harvard Medical School and the Weissman Lab at MIT/Whitehead Institute, with ARPA-H Program Manager Shannon Greene overseeing the initiative.
- • RNAV8 Bio's role focuses on translating RNA structure discoveries into viable therapeutic formats, addressing the practical gap between mRNA's theoretical programmability and real-world predictability in drug development.
Summary
RNAV8 Bio, a Cambridge-based biotechnology firm specializing in AI-driven mRNA medicine design, has been selected as a key member of a research consortium receiving ARPA-H (Advanced Research Projects Agency for Health) funding. The award, structured as a one-year pilot program, provides up to $4.4 million to support PROPEL (Programmable RNA for Optimal Precision in Therapeutic Efficacy and Localization), an initiative designed to advance the field of controllable RNA therapeutics.
The PROPEL program operates under leadership from Harvard Medical School's Rouskin Lab and MIT/Whitehead Institute's Weissman Lab, with ARPA-H Program Manager Shannon Greene directing the effort. The underlying scientific objective is to decode and operationalize RNA's natural folding behavior as a control mechanism for next-generation medicines. Unlike conventional gene therapy approaches that require genomic modification, PROPEL-funded research targets the development of logic-gated RNA constructs—therapies engineered to express exclusively where and when clinically intended, offering precision without permanent genetic alteration.
According to Devan Shah, Founder and Chief Executive Officer of RNAV8 Bio, the program directly addresses a fundamental challenge in mRNA therapeutics: the historical difficulty in predicting functional outcomes from RNA sequence and chemical composition alone. Shah stated that the collaboration aims to "learn the rules that connect sequence to function" and incorporate those rules into practical therapeutic constructs. RNAV8 Bio's specific contribution within the consortium focuses on translating laboratory discoveries about RNA structure into formats suitable for clinical development and regulatory submission—bridging the gap between fundamental science and drug manufacturing reality.
This funding allocation reflects continued institutional investment in precision RNA medicine platforms, positioning RNAV8 Bio within a high-priority U.S. biotech development initiative at a time when programmable therapeutics represent a significant frontier in pharmaceutical innovation.
The PROPEL program operates under leadership from Harvard Medical School's Rouskin Lab and MIT/Whitehead Institute's Weissman Lab, with ARPA-H Program Manager Shannon Greene directing the effort. The underlying scientific objective is to decode and operationalize RNA's natural folding behavior as a control mechanism for next-generation medicines. Unlike conventional gene therapy approaches that require genomic modification, PROPEL-funded research targets the development of logic-gated RNA constructs—therapies engineered to express exclusively where and when clinically intended, offering precision without permanent genetic alteration.
According to Devan Shah, Founder and Chief Executive Officer of RNAV8 Bio, the program directly addresses a fundamental challenge in mRNA therapeutics: the historical difficulty in predicting functional outcomes from RNA sequence and chemical composition alone. Shah stated that the collaboration aims to "learn the rules that connect sequence to function" and incorporate those rules into practical therapeutic constructs. RNAV8 Bio's specific contribution within the consortium focuses on translating laboratory discoveries about RNA structure into formats suitable for clinical development and regulatory submission—bridging the gap between fundamental science and drug manufacturing reality.
This funding allocation reflects continued institutional investment in precision RNA medicine platforms, positioning RNAV8 Bio within a high-priority U.S. biotech development initiative at a time when programmable therapeutics represent a significant frontier in pharmaceutical innovation.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.